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Abstract
Background: Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is a multisystem fibroinflammatory disease. We
previously reported that a circulating cell population expressing CD19+CD24−CD38hi was increased in patients with
IgG4-RD. In this study, we aimed to document that this cell population represented circulating plasmablasts/plasma
cells, to identify the detailed phenotype and gene expression profile of these IgG4-secreting plasmablasts/plasma
cells, and to determine whether this B-cell lineage subset could be a biomarker in IgG4-related disease (IgG4-RD).
Methods: A total of 42 untreated patients with IgG4-RD were evaluated. Peripheral B-cell subsets, including CD19
+CD24−CD38hi plasmablasts/plasma cells, CD19+CD24+CD38− memory B cells, CD19+CD24intCD38int naïve B cells,
and CD19+CD24hiCD38hi regulatory B cells, were assessed and sorted by flow cytometry. Microarray analysis was
used to measure gene expression of circulating B-cell lineage subsets. Further characterization of CD19+CD24
−CD38hi plasmablasts/plasma cells was carried out by evaluating additional surface markers, including CD27, CD95,
and human leukocyte antigen (HLA)-DR, by flow cytometric assay. In addition, various B-cell lineage subsets were
cultured in vitro and IgG4 concentrations were measured by cytometric bead array.
Results: In untreated patients with IgG4-RD, the peripheral CD19+CD24−CD38hi plasmablast/plasma cell subset was
increased and positively correlated with serum IgG4 levels, the number of involved organs, and the IgG4-related
Disease Responder Index. It decreased after treatment with glucocorticoids. Characterization of the plasmablast/
plasma cell population by gene expression profiling documented a typical plasmablast/plasma cell signature with
higher expression of X-box binding protein 1 and IFN regulatory factor 4, but lower expression of paired box gene
5 and B-cell lymphoma 6 protein. In addition, CD27, CD95, and HLA-DR were highly expressed on CD19+CD24
−CD38hi plasmablasts/plasma cells from patients with IgG4-RD. Furthermore, CD19+CD24−CD38hi plasmablasts/
plasma cells secreted more IgG4 than other B-cell populations.
Conclusions: Circulating CD19+CD24−CD38hi plasmablasts/plasma cells are elevated in active IgG4-RD and
decreased after glucocorticoid treatment. This IgG4-secreting plasmablast/plasma cell population might be a
potentially useful biomarker for diagnosis and assessing response to treatment.
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Background
Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is
a newly recognized fibroinflammatory disease character-
ized by infiltration of IgG4+ plasma cells together with
distinct storiform fibrosis in involved lesions and signifi-
cantly increased serum IgG4 levels [1–3]. There are vari-
ous clinical manifestations in patients with IgG4-RD,
including Mikulicz’s disease, autoimmune pancreatitis,
IgG4-related retroperitoneal fibrosis, pulmonary involve-
ment, kidney disease, sclerosing cholangitis, sinusitis,
sclerosing thyroiditis, and others [4–12].
IgG4-RD is characterized by a number of abnormalities
in the differentiation of cells of the B-cell lineage, includ-
ing increased serum levels of IgG, IgG4, and often IgE; in-
filtration of affected tissues by IgG4-secreting plasma; and
the presence of increased frequencies of circulating
plasma cells/plasmablasts [13–15]. B cells and plasma cells
may play important roles in the development of this dis-
ease [16]. Our previous studies revealed that, compared
with healthy control subjects and patients with primary
Sjögren’s syndrome, patients with IgG4-RD expressed an
increased circulating population of CD19+CD24−CD38hi
cells that appeared to be circulating plasmablasts/plasma
cells and correlated positively with serum IgG4 levels [17].
The full characterization of this circulating population
was not carried out, but its appearance and correlation
with serum IgG4 suggested that it might be an important
biomarker of IgG4-RD. To begin to address these ques-
tions, we initially characterized the circulating plasma-
blasts/plasma cells in IgG4-RD in greater detail.
Methods
Patients
Forty-two untreated patients with IgG4-RD fulfilling the
2011 comprehensive IgG4-RD diagnostic criteria were en-
rolled in this study. The diagnosis of IgG4-RD was based
on the following three manifestations: (1) clinical examin-
ation showing characteristic diffuse/localized swelling or
masses in single or multiple organs; (2) hematological
examination showing elevated serum IgG4 concentration
(>135 mg/dl); and (3) histopathologic examination showing
(a) marked lymphocyte and plasma cell infiltration and fi-
brosis or (b) infiltration of IgG4+ plasma cells (ratio of IgG4
+/IgG+ cells >40% and >10% IgG4+ plasma cells per high-
power field). Patients with cancer or lymphoma and other
autoimmune diseases were excluded.
Clinical data and inflammatory parameters
Clinical data, including age, gender, disease duration, and
manifestations, were obtained for all patients. Laboratory
findings were recorded, including erythrocyte sedimenta-
tion rate (ESR); C-reactive protein (CRP); and serum
immunoglobulin IgG, IgA, IgM, and IgG subsets. IgG4-
related Disease Responder Index (IgG4-RD RI) was calcu-
lated for each patient [18].
Flow cytometric analysis and separation of B-cell
subpopulations
Peripheral blood mononuclear cells (PBMCs) from
patients with IgG4-RD were separated by Ficoll
gradient centrifugation. Different B-cell populations




CD80, PE-anti-CD86, PE-anti-B-cell activating factor
receptor (BAFF-R), PE-anti-transmembrane activator
CAML (calcium modulator and cyclophilin ligand)
interactor (TACI), PE-anti-CD95, PE-anti-CD138, PE-
anti-interleukin-6 receptor (IL-6R), PE-anti-IgD, and
PE-anti-CD59 monoclonal antibodies (mAbs) (BD
Biosciences, San Jose, CA, USA), as well as PE-anti-
B-cell maturation antigen (BCMA) mAb (BioLegend,
San Diego, CA, USA), or isotype-matched controls.
After incubation for 30 minutes at 4 °C, the cells
were washed and resuspended in fluorescence-
activated cell sorting staining buffer (BD Biosciences).
All experiments were analyzed by gating on lympho-
cytes according to forward scatter/side scatter; dead
or dying cells or granulocytes were excluded. B-cell
subsets were gated on CD19 and then gated on CD24
and CD38. Flow cytometric analysis was performed
immediately after sample preparation. All samples
were analyzed using a BD FACSAria II system (BD
Biosciences), and data were analyzed by FlowJo
version 7.6.4 software (FlowJo, Ashland, OR, USA).
PBMCs were stained with CD19, CD24, and CD38 anti-
bodies and then sorted with a MoFlo high-performance
cell sorter (Beckman Coulter Life Sciences, Indianapolis,
IN, USA). Different B-cell subsets were separated, includ-
ing CD19+CD24+CD38− memory B cells, CD19
+CD24intCD38int naïve B cells, CD19+CD24hiCD38hi regu-
latory B cells (Bregs), and CD19+CD24−CD38hi plasma-
blasts/plasma cells. Sorted B-cell populations with purity
greater than 95% were used for in vitro culture and RNA
extraction.
In vitro cell culture
Purified B-cell populations from patients with IgG4-RD
were resuspended in RPMI 1640 medium supplemented
with 10% fetal calf serum and antibiotics (penicillin
100 IU/ml, streptomycin 100 μg/ml; Life Technologies,
Carlsbad, CA, USA) in 96-well U-bottomed plates
(Nunc, Langenselbold, Germany) in a humidified atmos-
phere of 5% CO2 at 37 °C with 1 × 10
5 cells in each well.
For each group, 100 ng/ml recombinant human CD40L
(Abcam, Cambridge, MA, USA) and 0.1 μg/ml cytosine
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phosphate guanosine oligodeoxynucleotide 2006 (CpG
ODN 2006; InvivoGen, San Diego, CA, USA) was added
at the beginning. After 7 days of culture, the levels of Ig
secretion in collected supernatants were tested.
Cytometric bead array analysis
Culture supernatant samples from different B-cell subsets
were collected and stored at −80 °C until used. Cytometric
bead array (CBA) analysis for IgG, IgA, IgM, IgG4, and
IgE in supernatants was performed according to the man-
ufacturer’s instructions (BD Biosciences). Data were ana-
lyzed using CBA analysis software obtained from BD
Biosciences. The concentrations of IgG, IgA, IgM, IgG4,
and IgE in supernatants were determined by reference to
a standard curve.
Microarray analysis of gene expression
Sorted B-cell subpopulations were placed in TRIzol reagent
(Life Technologies) for RNA extraction following the man-
ufacturer’s instructions. Isolated RNA was further purified
with the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and
processed for microarray analysis using the standard Affy-
metrix protocols (www.affymetrix.com; Affymetrix, Santa
Clara, CA, USA). Briefly, 1–10 μg of RNA was reverse-
transcribed into complementary DNA (cDNA) (Life Tech-
nologies). The template cDNA was purified for amplifica-
tion and in vitro transcription to cRNA using the
BioArray™ HighYield™ RNA Transcript Labeling Kit (T7)
(Enzo Life Sciences, Inc., Farmingdale, NY, USA). cRNA
was biotin-labeled, purified, and hybridized to Human Gen-
ome U133A GeneChips® (Affymetrix). GeneChips® were
scanned on a high-resolution scanner using GCOS version
1.2 software (Affymetrix). Data analysis was conducted after
standard Affymetrix algorithm analysis (MAS5).
Statistical methods
Statistical analyses were performed using IBM SPSS
Statistics version 19.0 software (IBM, Armonk, NY,
USA) and Prism software version 5.0 (GraphPad Soft-
ware, La Jolla, CA, USA). A P value <0.05 was consid-
ered significantly different. Data are reported as mean ±
SD. Normal distribution data between two groups were
analyzed using independent-samples t tests or paired-
samples t tests, and one-way analysis of variance
(ANOVA) was used to compare groups. The relation-
ships between CD19+CD24−CD38hi plasmablasts/plasma
cells and clinical features were analyzed by Pearson’s
rank correlation test, and a P value <0.05 was considered
significant. The level of gene expression was standard-
ized by robust multiarray average and detection above
background. One-way ANOVA was used to test different
levels of gene expression. The Benjamini-Hochberg
method was employed to determine the false discovery
rate after multiple hypothesis testing. A false discovery
rate <0.3 was used.
Results
Characteristics of patients with IgG4-RD
All 42 patients were newly diagnosed, untreated patients
with IgG4-RD. Their demographic features as well as clin-
ical and laboratory manifestations are listed in Table 1.
Their average age was 55 (41.5–60) years old, and the
male-to-female ratio was 2.23:1. Thirty-two (76.2%) of the
patients were characterized as definite IgG4-RD, 1 (2.4%)
was classified as probable IgG4-RD, and 9 (21.4%) were
categorized as possible IgG4-RD. The majority of patients
had multiple organ involvement. Forty-one (97.6%)
patients had elevated serum IgG4.
Table 1 Characteristics of 42 patients with immunoglobulin G4-
related disease
Characteristics Data
Age at evaluation, years, median (IQR) 55 (41.5–60)
Male/female ratio 2.23:1





Disease duration, months, median (IQR) 12 (5.75–36)
Number of organs involved, mean (SD) 4.33 (1.79)
Organs involved, n (%)
1 1 (2.4)
2 3 (7.1)
3 or more 38 (90.5)
Lymph nodes involved, n (%) 37 (88.1)
Salivary glands involved, n (%) 24 (57.1)
Lacrimal glands involved, n (%) 24 (57.1)
Pancreas involved, n (%) 13 (31.0)
Lung involved, n (%) 13 (31.0)
Prostate involved of male, n (%) 12 (41.4)
Paranasal sinus involved, n (%) 11 (26.2)
Retroperitoneal organs involved, n (%) 11 (26.2)
Bile duct involved, n (%) 8 (19.0)
Kidney involved, n (%) 6 (14.3)
Skin involved, n (%) 4 (9.5)
History of allergy, n (%) 29 (69.0)
Elevated serum IgG4 concentration at baseline, n (%) 41 (97.6)
Elevated IgE, n (%) 26/29 (89.7)
Eosinophilia, n (%) 16 (38.1)
Ig Immunoglobulin
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Correlations of CD19+CD24−CD38hi plasmablasts/plasma
cells with clinical and laboratory parameters in patients
with IgG4-RD
Our previous studies revealed that CD19+CD24−CD38hi
plasmablasts/plasma cells were significantly increased in
the peripheral blood of patients with IgG4-RD (6.99 ±
6.24%), higher than that in patients with Sjögren’s syn-
drome (2.39 ± 2.64%, P < 0.001) and healthy control sub-
jects (2.16 ± 1.65%, P < 0.001) [17]. The plot with the
gating strategy for identifying the different B-cell subpop-
ulations is shown in Fig. 1a. In this study, we further ana-
lyzed the association of these B-lineage populations with
clinical and laboratory parameters of IgG4-RD. Figure 1b–
h illustrates the correlations between CD19+CD24−CD38hi
plasmablasts/plasma cells and clinical/laboratory parame-
ters and shows that the ratio of CD19+CD24−CD38hi plas-
mablasts/plasma cells/CD19+ B cells correlated positively
with serum IgG4 (R = 0.4852, P = 0.0001), the numbers of
involved organs (R = 0.5039, P < 0.0001), and ESR (R =
0.3557, P = 0.0097), but that it had no correlation with
serum IgG (P = 0.0874), serum IgE (P = 0.6020), or CRP
(P = 0.2580). In addition, the absolute number of CD19
+CD24−CD38hi cells in patients with IgG4-RD was
markedly elevated at 7100/ml (2711–16,297/ml), com-
pared with 1475/ml (1021–2792/ml) in healthy subjects
(P < 0.001). Importantly, the absolute number of CD19
+CD24−CD38hi plasmablasts/plasma cells significantly
correlated with serum IgG4 as well (R = 0.3088, P =
0.0466) (Fig. 1c).
Differences in gene expression profiling among CD19
+C24−CD38hi plasmablasts/plasma cells, naïve B cells,
memory B cells, and regulatory B cells
To further analyze the characteristics of CD19+CD24
−CD38hi plasmablasts/plasma cells, we collected PBMCs
from 15 newly diagnosed patients with IgG4-RD, and the
following B cell subsets were sorted by flow cytometry:
Bregs (CD19+CD24hiCD38hi), memory B cells (CD19
+CD24+CD38−), naïve B cells (CD19+CD24intCD38int), and
plasmablasts/plasma cells (CD19+CD24−CD38hi). Because
the numbers of each B-cell subset were small, the subsets
of B cells from individual patients were pooled. Total RNA
was extracted for microarray analysis. Hierarchical cluster-
ing visualized by heat mapping indicated significant differ-
ences in gene expression by the four B-cell subsets (Fig. 2).
Importantly, CD19+CD24−CD38hi plasmablasts/plasma
Fig. 1 The correlations of CD19+CD24−CD38hi plasmablasts/plasma cells with clinical and laboratory parameters. a Gating strategy of CD19+CD24
−CD38hi plasmablasts/plasma cells. Correlations of the ratio of CD19+CD24−CD38hi plasmablasts/plasma cells and serum (b) immunoglobulin G4
(IgG4), (d) erythrocyte sedimentation rate (ESR), (e) IgG, (f) IgE, (g) C-reactive protein (CRP), and (h) involved organs are shown. c Correlation of
the absolute number of CD19+CD24−CD38hi plasmablasts/plasma cells and serum IgG4. SSC Side scatter
Lin et al. Arthritis Research & Therapy  (2017) 19:25 Page 4 of 14
cells were the most different from the other populations.
Among genes that were differentially upregulated in CD19
+CD24−CD38hi plasmablasts/plasma cells compared with
naïve B cells and memory B cells, we found those that are
known to alter the B-cell program and commit a B cell to
plasma cell differentiation, such as interferon regulatory
factor 4 (IRF4), PR domain containing 1 (PRDM1), and X-
box binding protein 1 (XBP1). Ig heavy and light chains as
well as J chain were also significantly upregulated, in
addition to those previously reported to be upregulated in
plasma cell genes, such as VDR, CAV1, SDC1, SSR4,
ERP70, PPIB, ITGA6, CD38, and others listed in Tables 2
and 3 [19–26]. Both IGK and IGL genes were upregulated,
implying the polyclonal nature of the plasma cell expansion.
Genes involved in plasma cell homing to tissue niches such
as SDC1 were also upregulated, although CXCR4, which is
also involved in homing of plasma cells to niches, was
downregulated. Finally, tumor necrosis factor receptor
superfamily member 17 (TNFRSF-17), which encodes
BCMA, a BAFF-R involved in plasma cell survival, was
Fig. 2 Gene expression of CD19+CD24−CD38hi plasmablasts/plasma cells, regulatory B cells (Bregs), memory B cells, and naïve B cells in patients
with immunoglobulin G4-related disease (IgG4-RD). B-cell subsets were sorted from the peripheral blood of patients with IgG4-RD, and total RNA
was extracted for microarray analysis. The differences among CD19+CD24−CD38hi plasmablasts/plasma cells and other B-cell subsets are shown.
Columns from left to right represent CD19+CD24−CD38hi plasmablasts/plasma cells, CD19+CD24intCD38int naïve B cells, CD19+CD24+CD38−
memory B cells, and CD19+CD24hiCD38hi Bregs, respectively. Red represents overexpressed genes, and blue represents underexpressed genes
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greatly upregulated in CD19+CD24−CD38hi plasmablasts/
plasma cells. As expected, BCR complex, CD19, CD20,
CIITA, human leukocyte antigen (HLA)-DRA, and HLA-
DRB1 gene expression was downregulated in CD19+CD24
−CD38hi plasmablasts/plasma cells. Likewise, the genes
characteristic of earlier stages of B-cell development or dif-
ferentiation, such as SPIB, BCL6, BLK, FYN, BCL11A,
CD37, CD1C,VAV3, CCR6, and CD22, were downregulated
significantly.
B-cell differentiation-related transcription factor genes in
CD19+CD24−CD38hi plasmablasts/plasma cells in patients
with IgG4-RD
The transcription factors regulating B-cell differentiation
into plasmablasts/plasma cells were analyzed in the various
B-cell subsets in greater detail (Fig. 3). In patients with
Table 2 Genes upregulated in CD19+CD24−CD38hi plasmablasts/
plasma cells of patients with immunoglobulin G4-related disease
Gene symbol Fold change Function
XBP1 17.2451 Transcription factor
ESR1 3.50117 Transcription factor
PRDM1 6.7131 Transcription factor
IRF4 3.88718 Transcription factor
TLR8 4.81882 Cell surface, intracellular signaling
SDC1 2.99145 Cell surface, intracellular signaling
CD59 12.8752 Cell surface, complexes with integrin
CD38 32.2263 Cell surface, intracellular signaling
IL6R 6.89689 Cell surface
PPIB 6.5266 Chaperone, unfolded protein response
HSPA13 7.91297 Chaperone, unfolded protein response
DNAJC1 3.01175 Chaperone, unfolded protein response
DNAJB9 2.97997 Chaperone, unfolded protein response
SSR3 6.50177 Protein assembly and trafficking
SSR4 5.70331 Protein assembly and trafficking
TNFRSF17 32.2516 Inhibitor of apoptosis
MAN1A1 5.35643 Posttranscriptional modification
VDR 16.5348 Transcriptional regulatory activity
ITGA6 2.21157 Integrin
IGHG 6.5159 Immunoglobulin heavy chain
IGH@ 6.4298 Immunoglobulin heavy chain
IGHA1 4.101 Immunoglobulin heavy chain
IGLC1 7.9258 Immunoglobulin light chain
IGLJ3 3.789 Immunoglobulin light chain
IGLL5 9.8509 Immunoglobulin light chain
IGLV1-44 8.2352 Immunoglobulin light chain
IGK@ 6.8981 Immunoglobulin kappa gene
IGKC 7.1539 Immunoglobulin kappa gene
CD27 4.65501 Apoptosis, signal transduction
CAV1 27.0908 Intracellular
IGF1 3.64001 Signal transduction
LTK 3.27963 Tyrosine kinase, intracellular signaling
GADD45A 4.13495 Cell cycle
CD44 2.23611 Cellular migration, cytokine receptor
activity
MKI67 5.39044 Cell proliferation
CCR10 2.16384 Chemokine receptor
Table 3 Genes downregulated in CD19+CD24−CD38hi
plasmablasts/plasma cells of patients with immunoglobulin
G4-related disease
Gene symbol Fold change Function
TRF8 –7.34056 Transcription factor
SPIB –4.91502 Transcription factor
PAX5 –7.43584 Transcription factor
FOXO1 –3.15445 Transcription factor, anti-apoptosis
STAT6 –3.06941 Transcription factor, signal transduction
CD72 –17.9585 Cell surface, intracellular signaling
CD37 –9.23361 Cell surface, intracellular signaling
CD40 –4.37638 Cell surface, signal transduction
CD24 –22.3673 Cell surface, intracellular signaling
CD1C –3.49943 Cell surface
CD19 –2.03392 Cell surface, signal transduction
SELL –2.59485 Cell surface, adhesion receptors
CD22 –8.40913 Cell surface, intracellular signaling
CXCR4 –5.3050 Chemokine receptor
CXCR5 –11.9723 Chemokine receptor
CCR6 –20.5228 Chemokine receptor





VAV3 –10.284 Signal transduction
IL6 –5.19 Cytokine
IL7 –9.61703 Cytokine
HLA-DRA –3.2849 Peptide antigen binding
BCR –7.43584 Kinase activity, protein binding
HLA-DRB1 –4.292155 Peptide antigen binding
FYN –2.82807 Tyrosine kinase
BLK –6.10205 Tyrosine kinase
BCL11A –14.6221 Transcriptional regulation activity
BACH2 –14.6267 Transcriptional regulation activity
ID3 –2.80866 Transcriptional regulation activity
CIITA –4.67153 HIA class II complex, transcription
coactivator
IGF1R –5.53806 Inhibitor of apoptosis
ITGB2 –2.37331 Integrin
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IgG4-RD, B-cell lymphoma 6 protein (BCL6) and PRDM1,
a pair of mutually restrictive transcription factors involved
in B-cell differentiation, showed opposite expression in
CD19+CD24−CD38hi plasmablasts/plasma cells compared
with the other three B-cell subsets, with BCL6 expression
being lower and PRDM1 expression higher in CD19+CD24
+CD38hi plasmablasts/plasma cells. In addition, compared
with the other three B-cell subsets, the expression of paired
box gene 5 (PAX5) in CD19+CD24−CD38hi plasmablasts/
plasma cells was much lower. Genes related to PAX5, in-
cluding IRF8, SPIB, Bach2, EBF, ID3, and CIITA, were also
downregulated. These results confirm that CD19+CD24
−CD38hi cells are plasmablasts/plasma cells.
Next, we analyzed other important genes related to the
differentiation of B cells. Compared with the other three
B-cell subsets, CD22 was markedly downregulated in
CD19+CD24−CD38hi plasmablasts/plasma cells, whereas
HLA class II genes (HLA-DRA, HLA-DRB1), CIITA, and
Fig. 3 The major transcription factors regulating B-cell differentiation into plasma cells. Analysis of transcription factor expression regulating B-cell
differentiation into plasma cells. Bars A to D indicate CD19+CD24−CD38hi plasmablasts/plasma cells, regulatory B cells, memory B cells, and naïve
B cells, respectively. *Difference of more than twofold by comparison of CD19+CD24−CD38hi plasmablasts/plasma cells with other B-cell subsets
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CD19 were significantly downregulated, compared with
memory and naïve B cells (Fig. 4, Tables 2 and 3). High ex-
pression of IGHD, IGJ, IGK, and IGHM are important in-
dicators for B-cell differentiation into plasma cells. In
CD19+CD24−CD38hi plasmablasts/plasma cells from pa-
tients with IgG4-RD, IGH gene expression was also mark-
edly increased, as was that of IGK and IGL genes. In
addition, the expression of CD27 and Fas/CD95 genes
was significantly higher than in the other three B-cell sub-
sets, whereas CD40 gene expression was decreased. CD23
was also markedly decreased in CD19+CD24−CD38hi plas-
mablasts/plasma cells of patients with IgG4-RD.
Analysis of B-cell proliferation-regulating genes and homing
factor genes
Marker of proliferation Ki-67 (MKI67), encoding the Ki-
67 protein and denoting recent cellular proliferation,
was markedly increased in CD19+CD24−CD38hi plasma-
blasts/plasma cells compared with the other three B-cell
subsets (Fig. 5). We also found that a number of genes
involved in cell homing, including SELL, which encodes
L-selectin (CD62L), was markedly increased, whereas ex-
pression of CCR7, CXCR5, and CXCR4 was greatly de-
creased, in CD19+CD24−CD38hi plasmablasts/plasma
cells compared with the other three B-cell subsets.
CCR10 expression was also markedly increased com-
pared with memory B cells and naïve B cells (Fig. 5).
Expression of activating factors of CD19+CD24−CD38hi
plasmablasts/plasma cells
By flow cytometric analysis, we compared the expression of
B-cell-activating factors and homing factors in different B-
cell subsets in patients with IgG4-RD (Fig. 6). This analysis
revealed that CD86, CD62L, HLA-DR, and CD95 were
highly expressed in CD19+C24−CD38hi plasmablasts/
plasma cells compared with other B-cell subsets. In particu-
lar, the majority of CD19+CD24−CD38hi B cells expressed
CD27 (76.46 ± 7.16%), which demonstrated that the CD19
+CD24−CD38hi population was a larger population that in-
cluded CD19+CD20−CD27+ plasmablasts/plasma cells.
Whereas CD138, BAFF-R, and BCMA were expressed by a
subset of CD19+CD24−CD38hi plasma/plasma cells, there
was almost no expression of TACI, CD23, CD40, IgE, and
IgD by this population.
Immunoglobulin secretion by different B-cell subsets in
IgG4-RD
The CD19+C24−CD38hi plasmablasts/plasma cells, Bregs,
memory B cells, and naïve B cells from patients with
IgG4-RD were isolated by cell sorting and cultured in
vitro. At day 7, the supernatants were collected, and the
secretion of immunoglobulin was tested.
The results showed that the IgG secreted by CD19
+CD24−CD38hi plasmablasts/plasma cells was 618.4 ±
163.3 ng/ml, much higher than that of Bregs and naïve B
cells (0.72 ± 0.59 ng/ml and 231.2 ± 44.83 ng/ml, respect-
ively; (P = 0.003 and P = 0.02, respectively), but that it was
not different from that of memory B cells (541.0 ±
252.1 ng/ml, P = 0.678). In addition, the IgG4 secreted by
CD19+C24−CD38hi plasmablasts/plasma cells was 176.1 ±
28.5 ng/ml, significantly higher than that secreted by
Bregs, memory B cells, and naïve B cells (0.87 ± 0.59 ng/
ml, P = 0.0005; 26.24 ± 7.08 ng/ml, P = 0.0009; and 5.34 ±
1.50 ng/ml, P = 0.0005, respectively). CD19+CD24−CD38hi
plasmablasts/plasma cells also secreted more IgE than
other B-cell subsets (3.14 ± 0.99 ng/ml, 2.01 ± 0.01 ng/ml,
2.01 ± 0.01 ng/ml, and 2.00 ± 0.01 ng/ml, respectively; P =
0.054). Regarding other immunoglobulins, there was no
significant difference in secreted IgA (20,573 ± 22,215 ng/
ml, 12.39 ± 1.96 ng/ml, 5209 ± 1066 ng/ml, and 12105 ±
16970 ng/ml, respectively; P = 0.37) and secreted IgM
(2090 ± 2401 ng/ml, 8.34 ± 1.75 ng/ml, 2385 ± 2402 ng/ml,
and 2810 ± 2387 ng/ml, respectively; P = 0.41) compared
Fig. 4 Expression of HLA class II genes in CD19+CD24−CD38hi plasmablasts/plasma cells, regulatory B cells, memory B cells, and naïve B cells
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with CD19+C24−CD38hi plasmablasts/plasma cells and
the other three subsets (Fig. 7).
Correlations of CD19+CD24−CD38hi plasmablasts/plasma
cells with disease activity and changes with treatment
Forty-two patients with IgG4-RD were assessed before
treatment with glucocorticoids, and 15 patients with
IgG4-RD were assessed both before and after
treatment with glucocorticoids. Before treatment, both
the ratio of CD19+CD24−CD38hi cells/CD19+ B cells
and the absolute number of CD19+CD24−CD38hi cells
correlated positively with disease activity in terms of
IgG4-RD RI (R = 0.575, P < 0.0001; R = 0.373, P =
0.015, respectively) (Fig. 8a, b). After treatment, along
with the decrease of IgG4-RD RI (from 13.48 ± 5.60
to 5.06 ± 2.38, P < 0.009) (Fig. 8f ), serum IgG (from
Fig. 5 Expression of proliferation genes, homing genes, and immunoglobulin genes in different B-cell subsets. B-cell proliferation genes, homing
genes, and immunoglobulin genes were analyzed in B-cell subsets in patients with immunoglobulin G4-related disease. a to l illustrate genes
differently expressed in B cell subsets. Bars A to D indicate CD19+CD24−CD38hi plasmablasts/plasma cells, regulatory B cells, memory B cells, and
naïve B cells, respectively. *Difference of more than two fold by comparison of CD19+CD24−CD38hi plasmablasts/plasma cells with other B-cell subsets
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Fig. 6 The phenotypic analysis of CD19+CD24−CD38hi plasmablasts/plasma cells determined by flow cytometry. CD19+CD24−CD38hi plasmablasts/
plasma cells were gated and then analyzed by flow cytometry. Red represents isotype control, and blue represents the expression level by CD19+CD24
−CD38hi plasmablasts/plasma cells. BAFF B-cell activating factor, BCMA B-cell maturation antigen, Ig Immunoglobulin, IL-6R Interleukin-6 receptor, TACI
Transmembrane activator CAML (calcium modulator and cyclophilin ligand) interactor
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25.74 g/L ± 12.55 g/L to 14.06 g/L ± 6.23 g/L, P <
0.001), and IgG4 (from 1740 mg/dl [7160–58,700] to
938 mg/dl [2900–17,300], P < 0.0001) (Fig. 8g, h),
both the absolute number (from 5914 [1888–19,487]/
ml to 2157 [822–3582]/ml, P = 0.005) and the ratio
(from 7.25% ± 6.35% to 2.55% ± 1.50%, P < 0.001) of
CD19+C24−CD38hi plasmablasts/plasma cells de-
creased significantly (Fig. 8c–e). By contrast, circulat-
ing memory B cells, which were also increased in
untreated patients [17], did not show significant
changes after steroid treatment. Notably, however,
there was no significant correlation between the mag-
nitude of decrease of the ratio of CD19+CD24−CD38hi
plasma cells and the decrease of the IgG4-RD RI (R =
0.505, P = 0.055) (data not shown).
Discussion
The data derived from the present study indicate that
CD19+CD24−CD38hi plasmablasts/plasma cells are sig-
nificantly elevated in the peripheral blood of patients
with IgG4-RD, and this B-cell population notably cor-
relates with the number of organs involved, serum
IgG4, IgG4-RD RI, and the ratio of IgG4/IgG. In
addition, peripheral CD19+CD24−CD38hi plasmablasts/
plasma cells decreased remarkably after treatment of
glucocorticoids, and the clinical manifestations of pa-
tients improved accordingly. These findings are con-
sistent with previous observations [17] and indicate
that the level of CD19+CD24−CD38hi plasmablasts/
plasma cells could be an important biomarker in
IgG4-RD.
Fig. 7 The secretion of immunoglobulin by regulatory B cells (Bregs), CD19+C24−CD38hi plasmablasts/plasma cells, memory B cells, and naïve B cells.
B-cell subsets, including CD19+CD24−CD38hi plasmablasts/plasma cells, Bregs, memory B cells, and naïve B cells from peripheral blood of patients with
immunoglobulin G4-related disease (IgG4-RD) were sorted by flow cytometry and underwent cell culture in vitro. After 7 days of cell culture with
CD40L and CpG ODN 2006, the supernatants were collected, and immunoglobulin secretion was analyzed. Horizontal histogram illustrates (a) IgG4,
(b) IgG, (c) IgE, and (d) IgM secreted by four subsets of B cells. Columns A–D represent Bregs, CD19+C24−CD38hi plasmablasts/plasma cells, memory B
cells, and naïve B cells, respectively. e Flow diagram of a representative patient with IgG4-RD. (*: P <0.05, **: P <0.01, ***: P <0.001)
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By gene expression analysis, we found that CD19
+CD24−CD38hi plasmablasts/plasma cells differed greatly
from the other three subsets of B cells, including naïve B
cells, memory B cells, and Bregs, and expressed many
genes typical of plasma cells. Considering that the gene
expression of CD19+CD24−CD38hi plasmablasts/plasma
cells differed from that of other known B-cell subsets,
we attempted to use gene expression analysis to deter-
mine their stage of plasma cell maturation. A number of
typical plasma cell genes were overexpressed, including
XBP1, PRDM1, IRF4, and TNFRSF17, whereas BCL6,
SPIB, and PAX5 were underexpressed, which is typical
of mature plasma cells. However, expression of these
genes does not permit a more detailed analysis of the
stage of maturation of plasma cells. It is known, how-
ever, that expression of HLA-DR can be employed to
identify newly generated cells from more mature plasma
cells; in this regard, CD19+CD24−CD38hi plasmablasts/
plasma cells from patients with IgG4-RD exhibited
bright expression of HLA-DR protein, as is typical of
newly formed plasma cells [27]. Notably, however, mes-
senger RNA (mRNA) levels of various major histocom-
patibility complex class II molecules were decreased, as
has been noted in systemic lupus erythematosus (SLE)
[22], suggesting that these plasma cells were transition-
ing from newly formed to more mature plasma cells that
had decreased mRNA expression but retained protein
expression of HLA-DR. Consistent with this, IgG4-RD
plasma cells greatly overexpressed Mki-67 mRNA, which
encodes the Ki-67 protein, a marker of recently divided
immunoglobulin-secreting plasma cells [28] and which
is increased in plasmablasts compared with memory B
cells [29]. Together, the increased expression of HLA-
DR protein but not mRNA and the increase in Mki-67
mRNA identify IgG4-RD plasma cells as newly gener-
ated and similar to those found in the circulation of
patients with SLE [30].
A number of other mRNAs and proteins were assessed
to further understand the maturation status of the IgG4-
RD plasma cells. The presence of mRNA for both
lambda and kappa light chains suggests that these CD19
+CD24−CD38hi plasmablasts/plasma cells are polyclonal,
although more detailed analysis on a single-cell level
would be required to confirm this. An interesting feature
of CD19+CD24−CD38hi plasmablasts/plasma cells was
their decreased expression of CXCR4. This chemokine
Fig. 8 The association between CD19+CD24−CD38hi plasmablasts/plasma cells and disease activity. a and b Correlations of the ratio of CD19+CD24
−CD38hi cells/CD19+ B cells and the absolute number of CD19+CD24−CD38hi plasmablasts/plasma cells with IgG4-related Disease Responder Index (IgG4-
RD RI) before treatment. c Change of CD19+CD24−CD38hi plasmablasts/plasma cells before and after treatment. d–h Ratios of CD19+CD24−CD38hi cells/
CD19+ B cells, absolute number of CD19+CD24−CD38hi plasmablasts/plasma cells, IgG4-RD RI, IgG, and IgG4 before and after treatment. *** P< 0.001,
**** P< 0.0001
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receptor uniquely recognizes CXCL12 and plays an im-
portant role in plasma cell homing to bone marrow and
other niches [31, 32]. The decreased expression of
CXCR4 could contribute to their persistence in the cir-
culation. A similar abnormality has been noted in SLE
plasma cells [22].
To further identify the characteristics of CD19+CD24
−CD38hi plasmablasts/plasma cells, we analyzed the sur-
face markers by flow cytometry, and we found that CD19
+CD24−CD38hi plasmablasts/plasma cells highly expressed
CD86, CD62L, IL-6R, CD27, and CD95, which was con-
sistent with those observed in gene levels. CD86 (B7-2)
signaling plays a pivotal role in activating T cells [33]. Ex-
pression of CD86 on B-lineage cells has been shown to
foster B-cell–T-cell collaboration and facilitate immuno-
globulin production, including IgE and IgG4 [34–39]. In
IgG4-RD, the CD19+CD24−CD38hi plasmablasts/plasma
cell subset highly expressed the CD86 molecule, suggest-
ing the intriguing possibility that this cell subset may
maintain some features of earlier B cells and, by virtue of
persistent expression of CD86, chronically stimulate T-cell
help and in so doing enhance the likelihood of class-
switching recombination to the downstream heavy-chain
isotypes IgG4 and IgE. The physiologic role of other mole-
cules expressed by CD19+CD24−CD38hi plasmablasts/
plasma cells requires delineation.
As previously reported, circulating plasmablasts identified
using CD19lowCD38+CD20−CD27+ phenotypic markers are
significantly elevated in active IgG4-RD, even in patients
with normal serum IgG4 concentrations, suggesting that
plasmablast counts are a potentially useful biomarker for
diagnosis of IgG4-RD as well as for assessing response to
treatment [13]. In our study, we found that 76.46% of
CD19+CD24−CD38hi cells expressed CD27, indicating that
the CD19+CD24−CD38hi plasmablasts/plasma cell popula-
tion is a larger one that contained CD19+CD20−CD27
+CD38hi cells. Similarly, the ratio of CD19+CD24−CD38hi
cells correlated positively with IgG4-RD RI, as did the abso-
lute number of CD19+CD24−CD38hi plasmablasts/plasma
cells [17]. Although there was no statistical correlation be-
tween the magnitude of change in circulating CD19+CD24
−CD38hi plasmablasts/plasma cells and the change in the
IgG4-RD RI, this may emerge when more patients are stud-
ied. Moreover, the significant correlation between disease
activity and circulating plasmablasts/plasma cells, as well as
the decrease in circulating plasma cells with therapy, sug-
gests that this might be useful in assessing these patients
and their response to treatment.
Conclusions
In this study, we found that CD19+CD24−CD38hi plasma-
blasts/plasma cells are prominently increased in peripheral
blood of untreated patients with IgG4-RD, correlating
positively with serum IgG4, IgG4/IgG ratio, IgG4-RD RI,
and the number of involved organs. This population de-
creased significantly after steroid treatment, suggesting
that CD19+CD24−CD38hi plasmablasts/plasma cells may
be a biomarker of IgG4-RD and potentially could be useful
in confirming a diagnosis, monitoring response to therapy,
or assessing disease activity.
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